SVRA Projected Dividend Yield

Savara Inc ( NASDAQ : SVRA )

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s product is a drug-device combination consisting of molgramostim nebulizer solution (drug component) and a vibrating mesh nebulizer (device component). Molgramostim nebulizer solution is vialed as a sterile formulation containing molgramostim solution. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system for administration of molgramostim nebulizer solution. The eFlow® consists of a controller unit, a nebulizer handset, and a connection cord.

20 YEAR PERFORMANCE RESULTS